Effects of Dapagliflozin on Hospitalisations in People with Type 2 Diabetes: Post-hoc Analyses of the DECLARE-TIMI 58 Trial
Lancet Diabetes Endocrinol. 2023;11:233–241 DOI: 10.1016/S2213-8587(23)00009-8
In patients with T2D at high risk of CV or kidney disease, SGLT2is consistently reduce the risk of HF hospitalisations. Less is known about their effects on hospitalisation from any cause, especially in patients with T2D without ASCVD, which includes most of the global population with T2D. Post hoc analyses of DECLARE-TIMI 58 assessed the effect of dapagliflozin on the risks of hospitalisations for any cause and for specific causes in patients with T2D with and without ASCVD.
Dapagliflozin reduced the risk of first and total non-elective hospitalisations for any cause in patients with T2D, regardless of the presence of ASCVD, including hospitalisations not directly attributed to cardiac, kidney or metabolic causes. The authors concluded that these findings might have implications on health-related quality of life for people with T2D and on health-care costs attributable this condition.
Keywords:
